Project Summary
Title: Systematic identification of novel anti-phage defense mechanisms in the E. coli pangenome
There is an urgent need for new therapies and approaches for treating antibiotic-resistant bacterial
infections. One promising, but underdeveloped approach called phage therapy aims to use the
viruses that infect bacteria, called bacteriophages (or just phages). Although there have been a
handful of case studies reporting success, including for the treatment of ESKAPE pathogens of most
dire concern, the long-term efficacy and prospects for wide-spread use of phage therapy remains
highly uncertain. A key challenge is that bacteria often harbor potent anti-phage defense mechanisms
that enable them to resist or overcome viral infection. These anti-phage mechanisms have emerged
from the long-standing, fierce coevolutionary battle between bacteria and phages, with a molecular
'arms race' leading bacteria to evolve diverse mechanisms for defending themselves and phages, in
turn, evolving counter-defense strategies. The anti-phage arsenal of bacteria includes restriction-
modification (RM) and CRISPR-Cas systems. In recent years computational studies have identified
dozens of additional systems, but these studies have critical limitations, and our own experimental
studies have indicated that there are dozens, and likely hundreds, of additional systems still to be
discovered. By developing and applying a powerful, high-throughput functional selection procedure,
we aim to identify the anti-phage systems present in a diverse collection of 1,500+ strains of E. coli,
including a range of pathogenic strains. We will screen for defense against a panel of 10 different
coliphages. Bioinformatic analyses, particularly homology detection and structural predictions, will be
done to assess the conservation, genomic context, and predicted biochemical functions of the newly
identified systems. Thus, our work will lay the foundation for detailed molecular studies of the diverse
new systems identified. As with prior studies of anti-phage defense, we anticipate that the new
systems will drive the discovery of new molecular mechanisms, which may, in turn, form the
foundation of a new generation of precision molecular tools. It has also become clear in recent years
that many cell autonomous components of eukaryotic innate immunity have distant homologs in
bacteria. As such, our work may also reveal evolutionarily conserved facets of immunity across the
kingdoms of life. Finally, the methodology developed will be broadly applicable to virtually any
bacterial pathogen, work that we anticipate will inform ongoing and future efforts to develop phages as
therapeutic agents.